ERBB2 and breast carcinoma: The CREATE-X and KATHERINE studies showed that capecitabine and T-DM1 improved 5-year DFS and 3-year iDFS rates by 13.7% and 11.3%, respectively, in TNBC and HER2-positive breast cancer patients who did not achieve pCR (37, 38).